BCM
ALNY icon

Bronte Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bronte Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Sell
37,245
-1,619
-4% -$551K 1.22% 20
2025
Q4 		$15.5M Buy
38,864
+3,890
+11% +$1.72M 1.54% 13
2025
Q3 		$17.8M Buy
+34,974
New +$14.2M 1.6% 15

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bronte Capital Management's ALNY Position: Q1 2026 in Review

Bronte Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.2% in Q1 2026, selling an estimated $551K and leaving 37,245 shares worth $12.3M. The position accounts for 1.22% of the portfolio, ranked #20.

Bronte Capital Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $17.8M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Bronte Capital Management held 37,245 shares of Alnylam Pharmaceuticals worth $12.3M as of Q1 2026.
  • Bronte Capital Management sold 1,619 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $551K.
  • Alnylam Pharmaceuticals made up 1.22% of Bronte Capital Management's portfolio in Q1 2026, its #20 holding.
  • Bronte Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Bronte Capital Management's Alnylam Pharmaceuticals position peaked at $17.8M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.